New combo therapy aims to shrink Hard-to-Treat colorectal tumors before surgery
NCT ID NCT07403877
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) or immunotherapy plus radiotherapy before surgery can improve outcomes for people with a specific genetic type of colorectal cancer called MSI-H/dMMR. About 114 participants will be randomly assigned to one of three treatment groups. The goal is to see which approach leads to more complete tumor shrinkage, potentially allowing some patients to avoid surgery altogether.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and ipilimumab (immunotherapy drugs), plus radiotherapy
What this could lead to
If successful, this could show that combining immunotherapy with or without radiotherapy before surgery helps shrink tumors more effectively in MSI-H colorectal cancer, potentially allowing some patients to avoid surgery.
What could go wrong
This is an early phase II trial with only 114 participants, so results may not apply to all patients. Immunotherapy can cause serious immune-related side effects, and adding radiotherapy may increase toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (MSI-H) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact